Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.
Journal: Journal for immunotherapy of cancer
Published: August 11, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 03, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 31, 2025
Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 07, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 31, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 03, 2025
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 13, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 06, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Journal: The New England journal of medicine
Published: September 16, 2024
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma.
Journal: NPJ precision oncology
Published: August 20, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 13, 2024
Last Updated: 09/26/2026